Writing in Nature, the group describes a myeloid-selective interleukin-10 receptor agonist, or msIL-10R agonist, a tetravalent nanobody-based molecule that reproduces IL-10’s potent suppression of inflammatory myeloid cells while leaving T cells untouched. The key insight came from a careful dissection of how different immune cells transmit the IL-10 signal. IL-10 normally binds IL-10Rα and IL-10Rβ to form a tetrameric receptor complex constitutively associated with the Janus kinases JAK1 and TYK2. When the cytokine engages the receptor, JAK1 must be activated through transphosphorylation, and the team found that cells can accomplish this through two parallel routes: TYK2-to-JAK1 or JAK1-to-JAK1. Crucially, the relative reliance on these routes differs dramatically between cell types.

To map these routes, the researchers used a selective allosteric JAK1 inhibitor called VVD-118313, which blocks JAK1 transphosphorylation without touching the kinase’s active site, alongside the TYK2 inhibitor zasocitinib and CRISPR-based gene knockout. In mouse bone-marrow-derived macrophages, blocking JAK1-to-JAK1 transphosphorylation only partially reduced IL-10-induced STAT3 phosphorylation and did not abolish the cytokine’s functional suppression of tumour necrosis factor. Only when TYK2 was also removed did signalling collapse completely, showing that at least one transphosphorylation route must remain intact. Human monocytes behaved similarly: TYK2 inhibition or knockout dented STAT3 phosphorylation but left the suppression of LPS-induced TNF and IL-6 fully intact.

T cells told a strikingly different story. In CD8-positive T cells, both pharmacological TYK2 inhibition and CRISPR knockout diminished IL-10-induced STAT3 phosphorylation and completely eliminated the cytokine’s augmentation of granzyme B and interferon-gamma production. T cells, in other words, depend strictly on TYK2 and on maximal pathway activation, whereas myeloid cells tolerate a substantially attenuated signal. The team confirmed this threshold logic with an engineered IL-10 monomer that engages only a single IL-10Rα–IL-10Rβ heterodimer, restricting signalling to one TYK2–JAK1 route. The monomer drove roughly half of maximal STAT3 phosphorylation in monocytes yet retained meaningful TNF suppression, while failing entirely to activate STAT3 or cytotoxic effector programs in T cells. Attenuation, it seemed, could be a feature rather than a bug.

Attenuated cytokines alone, however, make poor drugs. Previous IL-10 monomers and affinity-tuned muteins suffered from short half-lives, thermal instability, residual T and B cell activation and vulnerability to naturally occurring anti-IL-10 autoantibodies, which are common in inflammatory bowel disease. The team instead turned to single-domain antibodies. Alpacas were immunized with the extracellular domains of human IL-10Rα and IL-10Rβ, and phage-display libraries built from their B cells yielded diverse families of receptor-binding VHH domains. These were assembled into dimeric and tetravalent constructs pairing anti-IL-10Rα with anti-IL-10Rβ nanobodies, and screened in STAT3 reporter cells and primary human cells. Of 882 combinations tested, 182 showed reporter activity and 21 achieved more than 90 percent inhibition of TNF and more than 85 percent inhibition of IL-6 in LPS-stimulated blood cells.

Most of those hits, however, still recapitulated IL-10’s unwanted T cell stimulation. One construct stood apart. Designated the msIL-10R agonist, it pairs an anti-IL-10Rα nanobody called E07 with an anti-IL-10Rβ nanobody called A05 in each arm of an Fc scaffold, creating a tetravalent molecule with picomolar potency. It inhibited LPS-induced TNF with a half-maximal inhibitory concentration of 2.1 picomolar and IL-6 at 6.9 picomolar in human blood cells, while eliciting less than 10 percent of maximal STAT3 phosphorylation in CD4 and CD8 T cells, no induction of interferon-gamma or granzyme B, and no B cell proliferation or plasmablast differentiation. RNA sequencing confirmed that the molecule reproduced IL-10’s anti-inflammatory transcriptional program in resting and LPS-stimulated blood cells, including suppression of CSF3, IL6 and PTGES, yet induced no significantly differentially expressed genes in activated T cells.

Cryo-electron microscopy revealed why geometry matters so much. Using a fiducial Fab to enlarge the small receptor–nanobody complex, the team resolved the IL-10Rα–IL-10Rβ–E07-A05 assembly at 3.14 angstroms and a second IL-10Rα–E07 complex at 2.40 angstroms. The nanobody A05 binds an epitope on IL-10Rβ that partially overlaps the cytokine-binding surface but induces a local rearrangement of the Asn138–Trp143 loop, while E07 recognizes a broad surface spanning the junction of IL-10Rα’s two fibronectin type III domains, on the opposite side of the receptor from the IL-10 binding site. Notably, disease-associated IL10RA mutations such as Y64C and R117C, which cripple native IL-10 signalling and underlie very-early-onset inflammatory bowel disease, left the msIL-10R agonist’s activity fully intact, because the molecule engages epitopes spatially distinct from the cytokine interface.

Functional dissection showed that the tetravalent architecture is not negotiable. Disrupting either receptor-binding arm abolished STAT3 phosphorylation and cytokine suppression, maximal activity required simultaneous cross-linking of two IL-10Rα molecules with one or two IL-10Rβ molecules, and even subtle geometric changes were consequential. Shortening or lengthening the glycine-serine linker between E07 and A05 reduced activity, inverting the tandem nanobody order to A05-E07 abolished signalling entirely, and a symmetric A05-A05/E07-E07 arrangement boosted myeloid potency but restored roughly 20 percent of native IL-10’s interferon-gamma response in T cells. Signalling output, the authors conclude, is governed not simply by receptor occupancy but by the precise topology of receptor cross-linking, which forces the complex into a geometry that permits only TYK2-to-JAK1 transphosphorylation.

That strict TYK2 dependence, combined with receptor abundance, explains the selectivity. Myeloid cells express two- to eighteen-fold more surface IL-10Rα and IL-10Rβ than T, B or natural killer cells, providing the avidity needed to cluster the tetravalent agonist, whereas lymphocytes fall below the threshold. When the researchers forced T cells to overexpress IL-10Rα, and especially both receptor chains, STAT3 phosphorylation and granzyme B production returned, confirming receptor copy number as the critical determinant. The logic even proved portable: bispecific nanobodies pairing IL-10Rα with the lymphocyte-enriched IL-2Rγ chain redirected signalling toward T and NK cells, producing T/NK-selective agonists with minimal monocyte activity, again exquisitely dependent on geometry.

In vivo, the molecule delivered. In humanized IL10RA/IL10RB knock-in mice, it suppressed systemic TNF, IL-6 and IL-12 after LPS challenge as effectively as IL-10-Fc, reduced ear swelling and lymph node neutrophil infiltration in a delayed-type hypersensitivity model, and improved colon weight-to-length ratios, splenic neutrophil expansion and inflammatory gene expression in DSS-induced colitis. In cynomolgus monkeys, a humanized version showed dose-proportional exposure, sustained monocyte receptor occupancy and a terminal half-life of roughly eight days, with durable TNF suppression for more than three weeks after a single dose. Unlike IL-10-Fc, which elevated IL-18 and caused anaemia and thrombocytopaenia, the agonist produced no IL-18 elevation or haematological abnormalities at doses up to 100 milligrams per kilogram. The work establishes a geometry-based strategy for cell-type-selective cytokine engineering and positions the msIL-10R agonist as a promising candidate for inflammatory bowel disease and other myeloid-driven conditions, while offering a generalizable blueprint for precision cytokine therapeutics across immunology and oncology.

Subject of Research: Engineering a myeloid-selective IL-10 receptor agonist through TYK2-dependent signalling and receptor geometry

Article Title: Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism

Article References: Canaria, D. A., Nguyen, T. T. T., Huang, H., Xu, H., Yue, L., Fu, Y., Truong, H., Patel, K., Xing, W., Ravichandar, J. D., Xing, C., Martin, A. L., Delidakis, G., Wong, S., Pae, A., Yu, Y., Macdonald, R., Huang, Z., Main, M. C., … Yi, T. (2026). Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism. Nature. https://doi.org/10.1038/s41586-026-11176-1

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11176-1

Keywords: interleukin-10, IL-10 receptor, TYK2, JAK1, nanobody, myeloid cells, T cells, STAT3, cryo-electron microscopy, inflammatory bowel disease, cytokine agonism, immunotherapy

The research, led by a team working at the interface of mechanobiology and skin biology, addresses a long-standing puzzle in tissue physiology. Skin must maintain structural integrity while simultaneously accommodating growth, wound repair, and chronic mechanical stress such as repeated friction or tension. How a tissue senses these forces and translates them into molecular remodeling programs has been studied extensively at the level of individual mechanosensitive channels and cytoskeletal adapters. Far less is understood about which specialized cell subpopulations act as the conductors of this whole-tissue response.

Fibroblasts, the connective tissue workhorses of the dermis, have long been treated as a relatively uniform population of cells that deposit collagen and other extracellular matrix components. Over the past decade, single-cell technologies have shattered that view, revealing that fibroblasts exist in a spectrum of functionally distinct states, each occupying specific anatomical niches and performing specialized duties. Among the markers that have drawn intense interest is LGR5, a receptor best characterized as a Wnt target gene and a hallmark of adult stem cells in the intestine, hair follicle, and several other organs. Its appearance on a subset of dermal fibroblasts hinted that these cells might occupy a privileged regulatory position within skin.

The new findings place those LGR5-positive fibroblasts at the center of what the authors describe as skin mechanoadaptation, the process by which the tissue adjusts its architecture and mechanical properties in response to physical forces. According to the study, when skin is subjected to mechanical loading, these cells do not merely respond passively. Instead, they act as orchestrators, integrating mechanical cues and broadcasting instructions to surrounding cells through inflammatory and remodeling pathways, with JAK1 serving as a critical signaling node in that communication.

JAK1, or Janus kinase 1, is a cytoplasmic tyrosine kinase that relays signals from a family of cytokine receptors into the cell interior, most famously activating the STAT transcription factors that drive genes involved in immunity, cell growth, and tissue repair. Drugs targeting the JAK family have transformed the treatment of inflammatory diseases and certain cancers, making JAK1 one of the most pharmacologically scrutinized kinases in modern medicine. The revelation that JAK1 functions as a mechanotransductive regulator within a specialized fibroblast subset adds an entirely new dimension to its biological portfolio, and suggests that mechanical stress and inflammatory signaling in skin are more deeply intertwined than previously appreciated.

The implications extend well beyond basic cell biology. Excessive or aberrant mechanical stress is implicated in a range of cutaneous pathologies, from hypertrophic scarring and fibrosis to pressure ulcers and the progressive stiffening of aged skin. Conversely, insufficient mechanoadaptation can compromise wound closure and tissue resilience. If LGR5-positive fibroblasts genuinely coordinate the tissue-wide response to force through JAK1 signaling, then therapeutic strategies aimed at this specific cellular niche could, in principle, recalibrate how skin responds to stress, promoting healthy remodeling while dampening pathological fibrosis.

To reach these conclusions, the research team combined state-of-the-art lineage tracing with mechanical perturbation of skin tissue. Genetic fate-mapping approaches, in which cells expressing LGR5 and their descendants are permanently labeled, allowed the investigators to follow the behavior of this fibroblast subset under basal conditions and in response to mechanical challenge. Complementing the lineage studies, transcriptomic profiling revealed the molecular identity of the mechanoadaptive program, pinpointing JAK1-dependent signaling as a central feature of how these cells translate physical input into changes in gene expression and, ultimately, tissue architecture.

When the investigators disrupted JAK1 function in the context of mechanical loading, the coordinated adaptive response faltered, supporting the model that LGR5-positive fibroblasts require this kinase to fulfill their regulatory role. The finding reframes mechanotransduction not as a cell-autonomous affair confined to force-sensing proteins at the membrane, but as an intercellular program in which a small population of specialized stromal cells interprets mechanical context and modulates the behavior of the tissue as a collective. In this view, fibroblasts act less like passive scaffolding cells and more like mechanical stethoscopes and loudspeakers rolled into one, listening to the physical state of the skin and broadcasting chemical instructions accordingly.

For the broader field of mechanobiology, the study contributes to a growing recognition that stromal cells are active participants in how organs sense and respond to their physical environment. Similar sentinel populations have been described in other tissues, where specialized fibroblasts guide immune responses, organize repair zones after injury, and maintain niche architecture. The identification of an LGR5-marked, JAK1-modulating subset in skin strengthens the argument that tissue-level mechanoadaptation depends on a division of labor among fibroblast states, and that understanding this division of labor is essential for regenerative medicine.

Translational questions now loom large. Because JAK inhibitors are already in widespread clinical use, the findings raise the possibility that existing drugs, or more selective derivatives, could be repurposed to modulate skin mechanoadaptation in contexts ranging from scar prevention to anti-fibrotic therapy. At the same time, the study serves as a caution: wholesale blockade of JAK signaling in skin could interfere with beneficial adaptive remodeling, and the challenge ahead lies in achieving the right specificity, both at the level of the kinase and at the level of the cell type. As researchers work toward that precision, the humble dermal fibroblast, once dismissed as connective tissue filler, has firmly claimed its place as a master regulator of how skin meets the mechanical world.

The choice of LGR5 as a marker reflects a broader shift in how biologists identify functionally important cell types. Because LGR5 marks actively cycling stem cells in rapidly renewing epithelia, its expression in the dermis initially suggested that these fibroblasts might retain an unusual developmental plasticity. Fate-mapping studies in other organs have shown that LGR5-positive populations can generate diverse progeny, and the present work extends that logic to the stromal compartment, where a marked subset appears to exert influence less through self-renewal than through signaling authority over its neighbors.

The dermal microenvironment in which these cells reside is itself worth considering. The dermis is organized into papillary and reticular layers with distinct collagen densities, vascular supplies, and resident cell compositions, and fibroblasts occupying these layers differ in gene expression and in the mechanical properties of the matrix they produce. Mechanical forces impinging on the skin surface are transmitted through this layered architecture in complex ways, so a subset positioned at a particular depth or niche may be uniquely situated to sense deformation and relay that information to immune cells, endothelial cells, and epithelial stem cells above.

The connection between mechanical loading and cytokine signaling illuminated here also fits with accumulating evidence that physical forces can modulate inflammatory pathways independently of infection or tissue damage. Stretch, compression, and fluid shear have all been shown to alter cytokine production in cultured cells, and the JAK-STAT pathway is a common downstream convergence point for such signals. Placing JAK1 within a mechanotransductive circuit in intact skin provides an in vivo anchor for observations that had largely been made in simplified culture systems, where the multicellular architecture of real tissue is absent.

From a clinical standpoint, the findings intersect with a persistent therapeutic dilemma in dermatology. Antifibrotic interventions aim to reduce excessive collagen deposition, yet collagen synthesis is also essential for normal wound healing, and blunt suppression of matrix production can impair closure and strength of repaired skin. A regulatory node that acts specifically during mechanical adaptation offers a potential middle path: modulating it might allow clinicians to distinguish pathological responses to chronic aberrant loading from the beneficial remodeling that follows injury or surgical repair.

The study also speaks to the biology of skin aging, in which the dermis loses elasticity and becomes progressively stiffer, in part through changes in fibroblast number, phenotype, and extracellular matrix turnover. Whether the LGR5-positive mechanoadaptive population declines, shifts state, or becomes functionally silenced with age is an obvious next question, and one that could connect mechanoadaptation to the well-documented observation that aged skin heals more slowly and scars differently than young skin.

Methodologically, the work illustrates the value of combining lineage tracing with controlled mechanical perturbation, an approach that is becoming more common as researchers recognize that static snapshots of gene expression cannot capture how cells respond dynamically to force. Transcriptomic profiling under defined loading conditions, paired with genetic disruption of candidate signaling mediators, provides a framework that other groups studying lung, gut, or cardiovascular mechanobiology may adapt, since stromal sentinel populations are increasingly suspected in those organs as well.

Important caveats remain before the model can be considered complete. Mouse studies with genetic fate mapping do not automatically translate to human skin, whose dermal architecture and fibroblast heterogeneity differ in notable ways, and the precise identity of the upstream mechanical sensor in these cells has yet to be defined. Whether JAK1 modulation acts directly on mechanosensitive transcription or indirectly through cytokines released by neighboring cells will require careful dissection. Nonetheless, the demonstration that a defined fibroblast subset can govern tissue-wide mechanical adaptation marks a substantive step toward a cell-type-resolved understanding of how skin endures the physical demands of daily life.

Subject of Research: The role of LGR5-positive fibroblasts in coordinating skin mechanoadaptation via JAK1 signaling

Article Title: LGR5-positive fibroblasts orchestrate skin mechanoadaptation through JAK1 modulation

Article References: Fu, Q., Cheng, X., Chen, N., Sun, Y., Xu, L., Cheng, Y., Wang, C., Li, Y., Yu, T., Yan, Y., Zhang, W., Bu, Y., Lei, L., Chen, Y., Li, Z., Zhu, P., Wang, C., Zhang, L., Liu, C., & Li, Q. (2026). LGR5-positive fibroblasts orchestrate skin mechanoadaptation through JAK1 modulation. Nature Communications. https://doi.org/10.1038/s41467-026-77113-y

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77113-y

Keywords: LGR5, fibroblasts, skin, mechanoadaptation, JAK1, mechanotransduction, Nature Communications, dermis, tissue remodeling, JAK inhibitors, single-cell analysis, skin biology